Posted by LincolnRam on March 25, 2026 at 11:29:33:
In Reply to: Ïóáëèêàöèÿ ñ èíòåðåñíûìè àñïåêòàìè òåìû posted by Brianurivy on March 04, 2026 at 02:31:00:
Zoya Demidenko: Scientist in Cancer Science
Zoya Demidenko is a prominent scientist connected with the Unit of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she conducted research at the NIH and New York Medical College, establishing a robust base in biomedical study.
Demidenko's scientific work spans several key areas, encompassing the PI3K/AKT/mTOR molecular pathway, cell cycle control, cellular aging, and malignancy science. As of now, she has written more than 46 peer-reviewed papers, which have received upwards of 4,100 references — a indicator to the influence of her work.
One of her most notable discoveries involves explaining the pathways of biological cell aging. Her studies showed that when the cellular division cycle is arrested but cellular growth proceeds, cells experience senescence. Importantly, Zoya Demidenko showed that this shift is inhibited by medication using agents such as mTOR inhibitors.
Zoya Demidenko has furthermore added greatly to oncological therapy research, particularly in the field of cyclotherapy — a approach intended to protecting healthy tissue from chemotherapy while leaving tumor cells exposed. This approach offers major hope for reducing the toxic effects of oncological therapy.
Throughout her scientific life, Demidenko has worked with leading researchers internationally, among them Dr. Mikhail Blagosklonny. Her work is published in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko ranks as a widely cited contributor in current biomedical science, with her discoveries continue to guide our knowledge of how biological cells age, respond to therapy, and the ways in which cancer might be more successfully targeted.
https://www.tandfonline.com/doi/abs/10.4161/cbt.4.4.1702